title: MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
abstract: The annual "LabEx MAbImprove Industrial Workshops" are primarily intended to provide a comprehensive view about topics of interest for the pharmaceutical industry to scientists involved in research on therapeutic antibodies. The third workshop in this series, held July 2, 2015 in Tours, was dedicated to the optimization of delivery, namely all processes leading monoclonal antibodies to reach their target site. The commonly used intravenous (IV) route, although advantageous in terms of pharmacokinetics and pharmacodynamics, presents some disadvantages in terms of patients' convenience, therapeutic target access or treatment cost. Such problems led pharmaceutical companies to consider more straightforward and patient-friendly administration routes, bringing the need for specific formulations adapted to the specific inherent physicochemical challenges. In this context, the workshop provided an overview of these advances and opened discussion on new administration routes and formulation development. In the first session, the opportunities and challenges of 3 main routes of administration (IV, subcutaneous (SC), and pulmonary) were discussed, integrating protein stability issues. The next session was dedicated to medical devices intended for SC and pulmonary administration. The last session focused on specific formulations for monoclonal antibodies, particularly to successfully protect antibodies upon aerosolization, to develop highly concentrated formulations for SC administration, and to use formulation as a mean to overcome the barriers to oral protein delivery. As in the previous editions, this workshop gathered people from the academic and industrial spheres and allowed rich debates and discussions.
authors.affiliation: a Université François Rabelais, UMR 1100 , Tours , France.|b INSERM, Centre d'Etude des Pathologies Respiratoires, UMR , Tours , France.|c Service de Pharmacie, CHRU de Tours , Tours , France.
authors.forename: Elsa
authors.initials: E
authors.lastname: Bodier-Montagutelli
authors.affiliation: a Université François Rabelais, UMR 1100 , Tours , France.|b INSERM, Centre d'Etude des Pathologies Respiratoires, UMR , Tours , France.|c Service de Pharmacie, CHRU de Tours , Tours , France.
authors.forename: Renaud
authors.initials: R
authors.lastname: Respaud
authors.affiliation: a Université François Rabelais, UMR 1100 , Tours , France.|d Service d'Immunologie, CHRU de Tours , Tours , France.|e CNRS, Génétique, Immunothérapie, Chimie et Cancer, UMR , Tours , France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Watier
authors.affiliation: a Université François Rabelais, UMR 1100 , Tours , France.|f Groupe IMT , Tours , France.|g Bio3 Institute , Tours , France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Guillon-Munos
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003226:Congresses as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D005602:France; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal
keywords: Administration routes; aerosol; formulation; protein stability; therapeutic antibodies